Haleon PLC Sponsored ADR (NYSE:HLN) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Haleon PLC Sponsored ADR (NYSE:HLN) have received a consensus recommendation of “Moderate Buy” from the nine analysts that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, three have given a hold rating, three have assigned a buy rating and two have given a strong buy rating to the company.

HLN has been the topic of a number of recent analyst reports. Argus upgraded Haleon to a “strong-buy” rating in a report on Tuesday, March 17th. Rothschild & Co Redburn lowered Haleon from a “strong-buy” rating to a “hold” rating in a report on Tuesday, June 16th. Wall Street Zen raised shares of Haleon from a “hold” rating to a “buy” rating in a research report on Saturday, March 21st. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating on shares of Haleon in a research report on Thursday, April 30th.

Haleon Price Performance

Shares of NYSE:HLN opened at $9.26 on Friday. The company has a market cap of $40.86 billion, a price-to-earnings ratio of 23.73, a PEG ratio of 2.16 and a beta of 0.13. The company has a debt-to-equity ratio of 0.47, a current ratio of 0.92 and a quick ratio of 0.71. The firm has a 50 day simple moving average of $9.18 and a 200 day simple moving average of $9.86. Haleon has a one year low of $8.65 and a one year high of $11.28.

Haleon (NYSE:HLN) last released its quarterly earnings results on Saturday, February 14th. The company reported $6.32 earnings per share (EPS) for the quarter. The business had revenue of $3.65 billion for the quarter. Research analysts predict that Haleon will post 0.55 earnings per share for the current fiscal year.

Institutional Trading of Haleon

Several hedge funds and other institutional investors have recently modified their holdings of the business. Morgan Stanley raised its position in shares of Haleon by 16.0% in the fourth quarter. Morgan Stanley now owns 21,495,383 shares of the company’s stock valued at $217,318,000 after purchasing an additional 2,962,856 shares during the period. Norges Bank purchased a new position in Haleon during the fourth quarter valued at approximately $163,529,000. Arrowstreet Capital Limited Partnership grew its stake in Haleon by 82.8% during the first quarter. Arrowstreet Capital Limited Partnership now owns 14,674,518 shares of the company’s stock valued at $146,892,000 after acquiring an additional 6,647,329 shares in the last quarter. Bank of America Corp DE grew its stake in Haleon by 116.7% during the second quarter. Bank of America Corp DE now owns 12,384,135 shares of the company’s stock valued at $128,423,000 after acquiring an additional 6,669,923 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its stake in Haleon by 36.6% during the third quarter. JPMorgan Chase & Co. now owns 11,984,672 shares of the company’s stock valued at $107,503,000 after acquiring an additional 3,207,986 shares in the last quarter. Institutional investors own 6.67% of the company’s stock.

Haleon Company Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.